Aurobindo’s subsidiary, Eugia Pharma Specialties, has received the green light from the Food and Drug Administration to manufacture and market leuprolide acetate injection, 14 mg/2.8 ml MDV (Kit).
[Read more: Aurobindo obtains FDA OK for generic Lioresal]
Leuprolide acetate for injection, which is the generic of AbbVie's Lupron, is used to treat the symptoms associated with advanced prostate cancer by way of palliative treatment of advanced prostatic cancer.
The medication had a market value of roughly $83 million for the 12 months ending April 2022, according to IQVIA.
[Read more: Aurobindo obtains FDA approval for generic Colcrys]
Eugia Pharma Specialties Group, which manufactures oral and sterile specialty products, said it expects to launch the new generic this month.